A comparative study of the effect of low doses of acetylsalicylic acid and triflusal in the prevention of cardiovascular incidents in young adults with ischemic cerebrovascular disease;Estudio comparativo del efecto del acido acetilsalicilico en dosis bajas y el triflusal en la prevencion de eventos cardiovasculares en adultos jovenes con enfermedad cerebrovascular isquemica

Revista de Neurologia

Volumn 25, Issue 147, 1997, Pages 1669-1672

  Matias Guiu J ^a,c   Alvarez Sabin J ^b   Codina, A ^b  

^a Hospital General Universitari d'Alacant   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

Age; Antiplatelet drugs; Aspirin; Cerebrovascular disease; Ischemic cardiopathy; Stroke; Triflusal

Indexed keywords

ACETYLSALICYLIC ACID; SEDERGINE; TRIFLUSAL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN INFARCTION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; STROKE; THROMBOCYTE AGGREGATION INHIBITION;

ADULT; ASPIRIN; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; SALICYLATES; SURVIVAL RATE;

EID: 0030663552     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994: 308: 81-106.
2. The Canadian Cooperative Study Group. A randomized trial of aspirin and sulphinpirazone in threatening stroke. NEJM 1978: 299: 53-9.
3. Bousser MG, Landi G, Perrone P, et al. AICLA controlled trial of aspirin and dypiridamol in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 1983: 14: 5-14.
4. Hart RG, Harrison MJG. Aspirin wars. The optimal dose of aspirin to prevent stroke. Stroke 1996: 27: 585-7.
5. UK-TIA Study Group. The United Kingdom transient ischemic attack (UK-TIA) aspirin trial: Final reports. J Neurol Neurosurg Psychiatry 1991: 54: 1044-54.
6. UK-TIA Study Group. United Kingdom transient ischemic attack (UK-TIA) trial: Interim results. BMJ 1988: 296: 316-20.
7. The SALT collaborative group. Swedish aspirin low doses trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular secondary events. Lancet 1991: 338: 1345-9.
8. Francia E, Marín A, García Rafanell J. Triflusal. Antithrombotic agent. Drugs Fut 1978; 3: 225-8.
9. Triflusal: 15 años de experiencia farmacológica y clínica. Barcelona-Philadelphia: Prous-Science, Ed.; 1996. p. 1-6.
10. Gómez L, García Rafanell J, Forn J. Protective effect of triflusal and acetylsalicylic acid against arachidonic acid-induced cerebrovascular occlusion in anaesthetized rats. Meth Find Exp Clin Pharmacol 1987; 9: 13-7.
11. Heye N, Campos A, Kannuki S, Cervós-Navarro J. Effects of triflusal and acetylsalicylic acid on microthrombi formation in experimental brain ischemia. Exp Pathol 1991; 41: 31-6.
12. Blázquez Menes B, Salvador Agiar C, Navarro Izquierdo R, Fernández Díaz D. Ensayo con triflusal en el tratamiento y prevención de 50 accidentes vasculares cerebrales. Geriatrika 1985; 42-5.
13. García Moreno E, Manríquez Antón M, Orozco Carreras M, et al. Valoración clínica y analítica del triflusal, un antiagregante plaquetario en pacientes geriátricos con alto riesgo de enfermedad tromboembólica. Estudio multicéntrico a largo plazo. Anal Geriatr Gerontol 1985; 2: 125-9.
14. Smirne S, Ferini-Strambi L, Cucinotta D, Zamboni M, Ambrosoli L, Poli A. Triflusal and prevention of cerebrovascular attacks: Double-blind clinical study vs ASA. J Neurol 1994; 241 (Suppl 1): 53 (abstract).
15. Castellarnau C, Sancho MJ, Vila L, Albors, Rutllant ML. Effects and interaction studies of triflusal and other salicylic derivatives on cyclooxigenase in rats. Prostaglandins Leukot EFA 1988; 31: 83-9.
16. De la Cruz JP, Mata JM, Sánchez de la Cuesta F. Triflusal vs aspirin on the inhibition of human platelet and vascular cyclooxigenase. Gen Pharmac 1992; 23: 297-300.
17. García Rafanell J, Ramis J, Gómez L, Forn J. Effect of triflusal and other salicylic acid derivatives on cyclic AMP levels in rat platelets. Arch Int Pharmacodyn Ther 1986; 284: 155-65.
18. Álvarez J, Matías-Guiu J, Sumalla J, et al. Ischemic stroke in young adults I. Analysis of the etiological subgroups. Acta Neurol Scand 1989; 80: 28-34.
19. Matías-Guiu J, Álvarez J, Insa R, et al. Ischemic stroke in young adults II. Analysis of risk factors. Acta Neurol Scand 1990; 81: 314-7.
20. Ad Hoc Committee. A classification and outline of cerebrovascular diseases. Stroke 1975: 6: 565-616.
21. Matías-Guiu J, Dávalos A, Picó M, et al. Low-dose acetylsalicylic acid (AAS) plus dipyridamole versus dipyridamole alone in the prevention of stroke in patients with reversible ischemic attacks. Acta Neurol Scand 1987: 76: 413-21.
22. Barnett HMG, Kaste M, Meldrum BA, Eliaszin M. Aspirin dose in prevention of stroke. Stroke 1996: 27: 588-92.
23. Álvarez-Sabín J, Calvo G, Morros R. Prevención secundaria del ictus isquémico. Efecto de la dosis en el perfil de la aspirina. Rev Neurol 1997: 25: 541-4.
24. Triflusal versus acetylsalicylic acid in secondary prevention of cerebral infarction: TACIP study (Triflusal, Aspirin, Cerebral Infarction Prevention). Stroke 1997; 28.